The FDA has given the green light to the first major new classes of antidepressant therapies in decades, opening up new avenues for therapeutic development.
Clayton Larsen - President & CEO, Vesselon, Inc. | Oct 30, 2023 | 4 min read
Vesselon’s novel co-formulation of gas lipid microspheres and self-assembling liposomes, targeted and activated by commercial ultrasound, would be an ideal adjunct to any of these ADC drugs.
The US Food and Drug Administration last week approved the first of a new type of immunotherapy that aims to pit a patient’s own immune system against her cancer.
Twenty-five years after the enactment of the Bayh-Dole Act, scientists and administrators in academia who are interested in moving bench discoveries to the clinic are learning what travelers in London's subway system already know: It's important to "mind the gap."
Young researchers who left the academic path to transform their bright ideas into thriving companies discuss their experiences, and how you can launch your own business.